PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
SWTX SpringWorks Therapeutics
- 57.430
- -1.160-1.98%
Close Feb 14 16:00 ET
- 57.104
- -0.327-0.57%
Post 19:59 ET
4.27BMarket Cap-14.76P/E (TTM)
60.000High57.270Low2.78MVolume58.910Open58.590Pre Close162.75MTurnover4.03%Turnover RatioLossP/E (Static)74.39MShares60.00052wk High8.02P/B3.97BFloat Cap28.21052wk Low--Dividend TTM69.04MShs Float96.480Historical High--Div YieldTTM4.66%Amplitude13.600Historical Low58.520Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
SpringWorks Therapeutics Stock Forum
Historic FDA Approval: Groundbreaking NF1-PN Treatment Shows Remarkable 52% Response in Children
Breakthrough FDA Approval: New Drug Shows Remarkable 52% Response Rate in Children with Rare Tumor Disease
FDA: Approved Mirdametinib, for Adult & Pediatric Patients 2 Years of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable to Complete Resection
-Billionaire investor Stanley Druckenmiller told Bloomberg on Wednesday that selling all his Nvidia stock this year was a “big mistake.”
-Nvidia was Druckenmiller's top holding a year ago, but he sold it after the stock tripled in 2023.
-The shares are up another 174% this year, and Druckenmiller has missed much of the continuing rally.
Stanley Druckenmiller is an American billionair...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
No comment yet